Hypothesis

Senescent cells do not merely secrete soluble factors; they actively remodel the extracellular matrix (ECM) to create a stiff, cross‑linked niche that mechanically suppresses proliferation of neighboring stem and progenitor cells. This mechanochemical signal works in concert with the SASP to enforce a "hostage‑negotiator" state: the matrix transmits contractile forces that inhibit YAP/TAZ nuclear translocation, keeping progenitors quiescent. Chronic senescent cells sustain this loop through persistent NF‑κB/STAT3‑driven up‑regulation of lysyl oxidase (LOX) and LOXL2, which crosslink collagen and fibronectin. When senolytics remove these cells abruptly, the ECM remains over‑crosslinked for a short window, causing a transient surge in matrix stiffness that hyperactivates YAP/TAZ in progenitors, driving aberrant proliferation, faulty differentiation, and fibrosis rather than regeneration.

Mechanistic Rationale

• Senescent‑cell‑derived LOX – Senescent fibroblasts increase LOX expression via NF‑κB signaling (see SASP shift in chronic senescence) 6. LOX catalyzes oxidative deamination of lysine residues, forming aldehydes that condense into collagen cross‑links, raising tissue elastic modulus.
• ECM‑stiffness‑YAP/TAZ axis – Elevated stiffness promotes integrin‑FAK signaling, leading to LATS1/2 inhibition and YAP/TAZ nuclear entry, which drives transcription of proliferation genes (CTGF, CYR61) and pro‑fibrotic mediators (CTGF, TGF‑β1).
• Feedback to SASP – Nuclear YAP/TAZ can amplify NF‑κB activity, creating a feed‑forward loop that sustains inflammatory SASP even after senescent cell clearance, potentially explaining why some tissues show worsened inflammation post‑senolytic.
• Contrast with acute senescence – In wound healing, transient senescent cells deposit a modest, reversible LOX burst that aligns fibrin fibers without over‑crosslinking, providing a permissive scaffold for migration while still restraining premature proliferation 1.

Testable Predictions

1. Biochemical – In young mouse skin subjected to a standardized punch wound, conditional clearance of p16^INK4a^‑positive senescent cells (using p16‑3MR or INK‑ATTAC) at day 3 post‑injury will cause a significant increase in hydroxylysyl‑pyridinoline cross‑links (measured by HPLC) compared with controls given vehicle.
2. Mechanical – Atomic force microscopy on peri‑wound tissue will show a ~2‑3 fold rise in Young’s modulus 24 h after senolytic treatment, peaking before collagen deposition returns to baseline.
3. Signaling – Immunostaining for nuclear YAP/TAZ in Ki67^+^ progenitor cells will be elevated in senolytic‑treated wounds; pharmacological inhibition of LOX (β‑aminopropionitrile) or YAP (verteporfin) will normalize YAP/TAZ localization and reduce hyperproliferation.
4. Functional – Wounds treated with senolytics alone will develop thicker, collagen‑rich scar tissue (Masson’s trichrome) and delayed re‑epithelialization. Combining senolytics with LOX or YAP inhibitors will restore healing kinetics to that of untreated wounds.
5. Human relevance – In biopsies from diabetic ulcers (chronic senescent burden), LOX expression will correlate with p16^INK4a^ levels and inversely with nuclear YAP/TAZ in epithelial edges; ex‑vivo treatment of ulcer fibroblast cultures with senolytics will increase LOX activity and YAP nuclear shift, reversible by LOX knockdown.

Falsifiability

If senolytic clearance does not produce a measurable increase in ECM cross‑linking, YAP/TAZ activation, or fibrosis, or if LOX/YAP inhibition fails to rescue the phenotype, the hypothesis would be refuted. Conversely, consistent observation of the predicted mechanical and signaling changes would support the model that senescent cells act as a mechanochemical checkpoint whose abrupt removal can convert a protective arrest into a pathogenic proliferative burst.